Asset profile
SHR-1707
Monoclonal antibody
Evidence outlook
Phase 2 study terminated, no active studies registered
The furthest-phase study registered for this program (NCT06199037) was terminated, and no study is currently active on the registry. Earlier completed evidence carries a partial signal signal; the stopped study adds none. Check the registry record for the sponsor's stated reason.
NCT05681819: The trial randomized 33 participants to SHR-1707 or placebo with triple-blinding, a design able to isolate a genuine drug effect, but its primary outcomes were safety measures rather than a cognitive or functional efficacy endpoint, and results have not yet been posted, so no effect on Alzheimer's disease could be established from this record.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
71 competitors in this universe: 11 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 32 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| SHR-1707: this drug | Phase 2 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Remternetug | Phase 3 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Trontinemab | Phase 3 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| AV-1959R | Phase 2 | Vaccine | Amyloid-beta (monoclonal antibody) | ||
| Sabirnetug | Phase 2 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| ABBV-1758 | Phase 1/2 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| ALIA-1758 | Phase 1 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| ALZ-101 | Phase 1 | Vaccine | Amyloid-beta (monoclonal antibody) | ||
| CM383 | Phase 1 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| PMN310 | Phase 1 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Xanomeline / Trospium Chloride (Cobenfy) | Approved | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) |
…and 56 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
5 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.